TCNNF Quote, Financials, Valuation and Earnings

Nanoviricides has a net margin of -19.85% compared to Trulieve Cannabis's net margin of --. Trulieve Cannabis's return on equity of -11.52% beat Nanoviricides's return on equity of --.

Trulieve Cannabis has a consensus price target of $16.25, signalling upside risk potential of 303.23%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 392.42%. Given that Nanoviricides has higher upside potential than Trulieve Cannabis, analysts believe Nanoviricides is more attractive than Trulieve Cannabis.

Trulieve Cannabis has a beta of 1.435, which suggesting that the stock is 43.474% more volatile than S&P 500. In comparison Nanoviricides has a beta of 1.142, suggesting its more volatile than the S&P 500 by 14.225%.

Trulieve Cannabis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Trulieve Cannabis pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.

Trulieve Cannabis quarterly revenues are $301.1M, which are larger than Nanoviricides quarterly revenues of --. Trulieve Cannabis's net income of -$59.8M is lower than Nanoviricides's net income of -$2M. Notably, Trulieve Cannabis's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trulieve Cannabis is 0.65x versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics has a net margin of -19.85% compared to Trulieve Cannabis's net margin of --. Trulieve Cannabis's return on equity of -11.52% beat Oragenics's return on equity of --.

Trulieve Cannabis has a consensus price target of $16.25, signalling upside risk potential of 303.23%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 291.08%. Given that Trulieve Cannabis has higher upside potential than Oragenics, analysts believe Trulieve Cannabis is more attractive than Oragenics.

Trulieve Cannabis has a beta of 1.435, which suggesting that the stock is 43.474% more volatile than S&P 500. In comparison Oragenics has a beta of 0.847, suggesting its less volatile than the S&P 500 by 15.305%.

Trulieve Cannabis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Trulieve Cannabis pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

Trulieve Cannabis quarterly revenues are $301.1M, which are larger than Oragenics quarterly revenues of --. Trulieve Cannabis's net income of -$59.8M is lower than Oragenics's net income of -$3.3M. Notably, Trulieve Cannabis's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trulieve Cannabis is 0.65x versus 1.59x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -19.85% compared to Trulieve Cannabis's net margin of -2357.27%. Trulieve Cannabis's return on equity of -11.52% beat Palatin Technologies's return on equity of --.

Trulieve Cannabis has a consensus price target of $16.25, signalling upside risk potential of 303.23%. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 818.15%. Given that Palatin Technologies has higher upside potential than Trulieve Cannabis, analysts believe Palatin Technologies is more attractive than Trulieve Cannabis.

Trulieve Cannabis has a beta of 1.435, which suggesting that the stock is 43.474% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.793, suggesting its less volatile than the S&P 500 by 20.66%.

Trulieve Cannabis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Trulieve Cannabis pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Trulieve Cannabis quarterly revenues are $301.1M, which are larger than Palatin Technologies quarterly revenues of $350K. Trulieve Cannabis's net income of -$59.8M is lower than Palatin Technologies's net income of -$2.4M. Notably, Trulieve Cannabis's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trulieve Cannabis is 0.65x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -19.85% compared to Trulieve Cannabis's net margin of --. Trulieve Cannabis's return on equity of -11.52% beat Theriva Biologics's return on equity of --.

Trulieve Cannabis has a consensus price target of $16.25, signalling upside risk potential of 303.23%. On the other hand Theriva Biologics has an analysts' consensus of $6.00 which suggests that it could grow by 400%. Given that Theriva Biologics has higher upside potential than Trulieve Cannabis, analysts believe Theriva Biologics is more attractive than Trulieve Cannabis.

Trulieve Cannabis has a beta of 1.435, which suggesting that the stock is 43.474% more volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.159, suggesting its more volatile than the S&P 500 by 15.945%.

Trulieve Cannabis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Trulieve Cannabis pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Trulieve Cannabis quarterly revenues are $301.1M, which are larger than Theriva Biologics quarterly revenues of --. Trulieve Cannabis's net income of -$59.8M is lower than Theriva Biologics's net income of -$4.4M. Notably, Trulieve Cannabis's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trulieve Cannabis is 0.65x versus 1.59x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.